Actively Recruiting
Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma
Led by University of California, San Francisco · Updated on 2026-04-01
40
Participants Needed
1
Research Sites
249 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
P
Pacific Pediatric Neuro-Oncology Consortium
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy of Laser Interstitial Thermal Therapy (LITT) in treating recurrent or progressive, low-grade gliomas (LGG) in pediatric, adolescent and young adult patients.
CONDITIONS
Official Title
Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have recurrent or progressive pediatric low-grade glioma (LGG) confirmed by histology and be candidates for LITT after prior treatment including surgery and/or systemic therapy.
- Tumor size up to 5 cm in largest dimension, excluding cystic components; larger tumors require discussion.
- Tumors must be located in brain or central nervous system areas accessible and safe for LITT as determined by central review.
- Suprasellar gliomas not arising from the optic pathway are eligible.
- Multifocal or metastatic LGGs are eligible if growing lesions are suitable for LITT.
- Exophytic brainstem lesions may be eligible.
- Stable leptomeningeal disease with a separate growing lesion suitable for LITT is allowed.
- Prior LITT allowed only if new lesion not previously treated or if progression occurred after 15 months.
- Participants must have recovered from toxic effects of prior therapies and be eligible for surgery.
- Last bevacizumab dose must be more than 21 days before registration.
- Last chemotherapy dose > 3 weeks prior (6 weeks for nitrosoureas or mitomycin C).
- At least 7 days since last biologic or small molecule therapy, accounting for known adverse event timing.
- Last fraction of local irradiation or focal radiosurgery at least 12 weeks before registration.
- Last fraction of craniospinal or total body irradiation at least 12 weeks before registration.
- Age between 2 and 25 years.
- Performance score of Karnofsky ≥ 50 for >16 years old or Lansky ≥ 50 for ≤16 years old; wheelchair-bound participants considered ambulatory.
- Stable or decreasing dexamethasone dose for at least 1 week prior.
- Surgically eligible per institutional standards.
- Must co-enroll in Pediatric Neuro-oncology Consortium COMP if available.
- Informed consent and assent obtained as appropriate.
You will not qualify if you...
- Contraindications to LITT including optic pathway gliomas, spinal tumors, infiltrative brainstem lesions, or any lesion/location deemed unsafe by central review.
- Presence of uncontrolled leptomeningeal or extracranial disease.
- Untreated obstructive hydrocephalus or mass effect causing >10 mm midline shift.
- Symptomatic intratumoral hemorrhage grades 3 and 4; grade 2 requires discussion.
- Receiving other investigational agents.
- Uncontrolled intercurrent illness including active infections.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
P
PNOC Operations Office
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here